Back to discover

Protein / target

DNA-directed RNA polymerase subunit beta'

rpoCQ18CF3Clostridioides difficile (strain 630)Swiss-Prot
24
Clinical trials
1
Drugs targeting

Protein at a glance

Biological role

DNA-directed RNA polymerase

Derived from structured UniProt, Open Targets and literature data on this page.

Protein profile

UniProt 2026_02

Canonical identity and biological annotation from UniProt.

Function overview

DNA-dependent RNA polymerase catalyzes the transcription of DNA into RNA using the four ribonucleoside triphosphates as substrates

Domains and Gene Ontology detail (6)

Gene Ontology

  • CDNA-directed RNA polymerase complex
  • FDNA binding
  • FDNA-directed RNA polymerase activity
  • Fmagnesium ion binding
  • Fzinc ion binding
  • PDNA-templated transcription

1161 aa · 130 kDa

Biological roles

What this protein does, drawn together from its UniProt function, Gene Ontology terms and Reactome pathways.

Transcriptional regulationUniProt · GO
View supporting evidence

Transcriptional regulation

  • ·DNA-dependent RNA polymerase catalyzes the transcription of DNA into RNA using the four…
  • ·DNA-templated transcription

Concepts derived from UniProt GO Reactome — each badge above shows which sources supported that role.

Approved medicines with mapped indications

1 medicine · 3 areas

Approved therapies targeting this protein, grouped by what they are approved to treat — the disease-first view of the medicines below. Relationships come from the canonical approved-indication graph (ChEMBL phase-4), the same source as the drug cards.

Clostridium Infections1 medicine
Diarrhea1 medicine
Infections1 medicine

Approved indications from ChEMBL (phase-4), via the canonical drug→disease graph.

Drugs targeting this protein

1

How approved and investigational drugs engage this protein — mechanism and action type, direct vs complex targeting, and how broadly each acts across other targets. A drug-first view (the section above groups the approved ones disease-first); direct binders with few recorded targets are listed first.

Fidaxomicin
Inhibitor

DNA-directed RNA polymerase inhibitor

Indicated for Clostridium Infections, Diarrhea, Infections

Acts on a complex — shared with rpoB, rpoA, rpoZ · 1 of 4 recorded protein targets

ChEMBL mechanism, action type, target identity and approved indications. Open Targets clinical status.

Clinical trials

24

Trials of drugs that target this protein — reached indirectly through those drugs, so a trial listed here studies the drug, not the protein. Ranked by active status, then clinical phase and recency, and spread across the targeting drugs.

View all trials (20)

TERMINATED · via Fidaxomicin · NCT02667418

ClinicalTrials.gov via the drug-target graph.

What's happening now

4

Recent therapeutic activity around this target — regulatory actions, clinical trials and safety signals for a drug that targets this protein, plus publications where such a drug is a genuine subject. Every item is reached indirectly through the drug, not the protein itself; incidental mentions (a paper that merely measures a drug) and press items are excluded.

  1. Regulatory approval2026-08-13

    Approval: FIDAXOMICIN (ANDA220465)

    fda · regulatory · fda · via Fidaxomicin

  2. New publication2018-08-01
    Safety and Pharmacokinetic Study of Fidaxomicin in Children With Clostridium difficile-Associated Diarrhea: A Phase 2a Multicenter Clinical Trial.

    Journal of the Pediatric Infectious Diseases Society · 2018 · 18 citations · Europe PMC · via Fidaxomicin

  3. Regulatory approval2011-12-05

    Approval: Dificlir (EMA)

    ema · regulatory · ema · via Fidaxomicin

  4. New publication2011-02-01
    Fidaxomicin versus vancomycin for Clostridium difficile infection.

    The New England journal of medicine · 2011 · 1,120 citations · Europe PMC · via Fidaxomicin

Objective event titles are shown unmodified; the event kind and significance line are derived from structured fields. Forefront AttentionEvent stream aggregating Europe PMC Regulatory filings ClinicalTrials.gov.